Hyderabad: Biological E has registered with the World Health Organization (WHO) for EUL (list of emergency use) of the corbevax recombinous protein sub-unit vaccine.
The company expects to start vaccine supplies to the Indian government immediately, Biological E MD Mahima Datla told TI during exclusive interactions.
“Wegot DCGI (Indian General Control Medication) EUA on December 28, 2021.
As soon as we submit all the data needed for whom EUL / PQ.
The review usually takes six months, but I hope it will be shorter in our case.
All of our vaccines are The prequalification so that it’s not our first experience.
We are very experienced with whom the requirements of the infrastructure point of view, so I hope all this will play their role in speeding up the reviews, “Datla said.
He said that once EUL is ready, a protein subunit vaccine can be supplied to around 70% of world countries.
“In parallel, we also work with several countries to register Corbevax and start inventory interim.
Global demand projections will be completed in the near future,” he said.
‘Bio E produces 25 doses of Corbevax’taking crore about supplying to the Indian government, Datla said Bio E has produced 25 doses of Corbevax Crore and hopes to complete the production of the initial supply commitment of 30 doses of Crore on February 15.
“This 25 dose of crore, 65 million has been removed by the CDL (Central Medicines Laboratory), Kasauli, and 120 million other doses are waiting for release, while the remaining doses are produced in the process of submitting to the CDL,” he said.
The company has increased the annual capacity of the dose to100 crore (1 billion) for Corbevax and can even increase up to 1.2 billion doses every year.
“We can increase it to 2 billion doses (if necessary),” he explained.
Datla refused to reveal the price of Corbevax.
“In line with our goal of being the most affordable vaccine, it will be lower than RS150 per dose for government inventory.” “We will save ex-checkers at least Rs1,500 Crore on our own order if we compare it to the price of others.
But I hand it over to the government’s policy to reveal the price,” he said.
However, in the private market the company will choose a differential price determination strategy.
“We don’t want to be wasteful in the private market and want to make sure it can be accessed even there.
We are still working on private market price logistics but I can tell you that it will be very reasonable,” he said.